Amgen Inc
AMGN309.850USD
+4.150+1.35%
Cierre 04/03, 16:00（ET）Cotizaciones retrasadas 15 min
166.36BCap. mercado
40.67P/E TTM
Información de Amgen Inc Compañía
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Información de la empresa
Código de la empresaAMGN
Nombre de la empresaAmgen Inc
Fecha de salida a bolsaJun 17, 1983
Fundada en1986
Director ejecutivoMr. Robert A. (Bob) Bradway
Número de empleados28000
Tipo de títulosOrdinary Share
Fin del año fiscalJun 17
DirecciónOne Amgen Center Drive
CiudadTHOUSAND OAKS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal91320-1799
Teléfono18054471000
Sitio Webhttps://www.amgen.com/
Código de la empresaAMGN
Fecha de salida a bolsaJun 17, 1983
Fundada en1986
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
467.36K
+2.83%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
67.76K
+5.28%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
38.85K
+11.62%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
16.00K
+4.70%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President of Human Resources
Senior Vice President of Human Resources
9.39K
+12.92%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
8.96K
+11.36%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
7.05K
+16.11%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
6.60K
+12.23%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
6.54K
+12.34%
Ms. Amy E. Miles
Ms. Amy E. Miles
Independent Director
Independent Director
3.93K
+22.41%
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
467.36K
+2.83%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
67.76K
+5.28%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
38.85K
+11.62%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
16.00K
+4.70%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President of Human Resources
Senior Vice President of Human Resources
9.39K
+12.92%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
8.96K
+11.36%
Desglose de ingresos
Divisa: USDHora de actualización: mié., 2 de abr
Divisa: USDHora de actualización: mié., 2 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Other products
5.63B
16.84%
Prolia
4.37B
13.09%
Enbrel
3.32B
9.92%
XGEVA
2.23B
6.66%
Repatha
2.22B
6.65%
Other
15.66B
46.84%
Por regiónUSD
Nombre
Ganancia
Proporción
US
23.30B
69.71%
ROW
8.72B
26.10%
Other revenues
1.40B
4.18%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Other products
5.63B
16.84%
Prolia
4.37B
13.09%
Enbrel
3.32B
9.92%
XGEVA
2.23B
6.66%
Repatha
2.22B
6.65%
Other
15.66B
46.84%
Accionista
Hora de actualización: vie., 21 de feb
Hora de actualización: vie., 21 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
9.77%
State Street Global Advisors (US)
5.48%
BlackRock Institutional Trust Company, N.A.
5.36%
Charles Schwab Investment Management, Inc.
2.46%
PRIMECAP Management Company
2.42%
Other
74.51%
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
9.77%
State Street Global Advisors (US)
5.48%
BlackRock Institutional Trust Company, N.A.
5.36%
Charles Schwab Investment Management, Inc.
2.46%
PRIMECAP Management Company
2.42%
Other
74.51%
Tipo
Accionista
Proporción
Investment Advisor
40.03%
Investment Advisor/Hedge Fund
29.85%
Research Firm
4.32%
Pension Fund
2.24%
Bank and Trust
2.06%
Hedge Fund
1.62%
Sovereign Wealth Fund
1.22%
Insurance Company
0.57%
Individual Investor
0.16%
Other
17.94%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
4383
443.64M
82.58%
+3.03M
2024Q4
4466
443.40M
82.54%
+89.78K
2024Q3
4316
438.01M
81.42%
-5.13M
2024Q2
4284
437.79M
81.61%
-4.94M
2024Q1
4192
436.25M
81.40%
-5.11M
2023Q4
4150
435.28M
81.36%
+42.25K
2023Q3
3990
429.94M
80.36%
-4.48M
2023Q2
3936
426.14M
79.65%
-4.34M
2023Q1
3951
427.29M
80.00%
-4.36M
2022Q4
3946
428.59M
80.25%
-5.45M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
52.49M
9.77%
+346.49K
+0.66%
Dec 31, 2024
State Street Global Advisors (US)
29.43M
5.48%
+117.40K
+0.40%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
28.79M
5.36%
+444.90K
+1.57%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
13.21M
2.46%
+2.67M
+25.38%
Dec 31, 2024
PRIMECAP Management Company
13.00M
2.42%
-1.25M
-8.80%
Dec 31, 2024
Geode Capital Management, L.L.C.
12.48M
2.32%
+352.14K
+2.90%
Dec 31, 2024
Capital International Investors
12.21M
2.27%
+3.50M
+40.10%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
11.12M
2.07%
+149.28K
+1.36%
Feb 28, 2025
Morgan Stanley Smith Barney LLC
8.37M
1.56%
-185.43K
-2.17%
Dec 31, 2024
Wells Fargo Advisors
6.91M
1.29%
-231.48K
-3.24%
Dec 31, 2024
Ver más
ETF relacionados
Hora de actualización: mié., 2 de abr
Hora de actualización: mié., 2 de abr
Nombre
Proporción
VanEck Biotech ETF
17.51%
FT Vest DJIA Dogs 10 Target Income ETF
13.78%
ProShares Ultra Nasdaq Biotechnology
9.01%
Invesco Nasdaq Biotechnology ETF
9.01%
iShares Biotechnology ETF
8.22%
Amplify Weight Loss Drug & Treatment ETF
5.87%
Amplify CWP Enhanced Dividend Income ETF
5.51%
Invesco Biotechnology & Genome ETF
5.22%
Invesco Pharmaceuticals ETF
5.18%
Monarch Blue Chips Core ETF
4.58%
Ver más
VanEck Biotech ETF
Proporción17.51%
FT Vest DJIA Dogs 10 Target Income ETF
Proporción13.78%
ProShares Ultra Nasdaq Biotechnology
Proporción9.01%
Invesco Nasdaq Biotechnology ETF
Proporción9.01%
iShares Biotechnology ETF
Proporción8.22%
Amplify Weight Loss Drug & Treatment ETF
Proporción5.87%
Amplify CWP Enhanced Dividend Income ETF
Proporción5.51%
Invesco Biotechnology & Genome ETF
Proporción5.22%
Invesco Pharmaceuticals ETF
Proporción5.18%
Monarch Blue Chips Core ETF
Proporción4.58%
Dividendos
Un total de
21.35B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
Mar 07, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Dec 12, 2022
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 08, 2023
Feb 14, 2023
Oct 28, 2022
AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 08, 2022
Nov 16, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados